Navigation Links
Dendreon Announces Presentation of PROVENGE Data at the 2011 Genitourinary Cancers Symposium Annual Meeting
Date:2/17/2011

s who did not receive APC8015F (HR=0.52 [95% CI: 0.37, 0.73]; P=0.0001).  While baseline prognostic factors tended to be more favorable in patients who received APC8015F, treatment with APC8015F remained associated with improved survival after adjusting for these factors (HR=0.55 [95% CI: 0.39, 0.78]; P<0.001).  The safety profile of APC8015F was consistent with that observed in the PROVENGE Phase 3 clinical trials.

Abstract #155: Characterization of Antigen-Specific T cell Activation and Cytokine Expression Induced by Sipuleucel-T

In PROVENGE (sipuleucel-T) Phase 2 and 3 clinical trials, patients underwent leukaphereses to collect peripheral blood mononuclear cells (PBMCs).  For the patients randomized to receive sipuleucel-T, the patient's PBMCs were cultured with PA2024, a recombinant fusion protein consisting of prostatic acid phosphatase (PAP) and granulocyte-macrophage colony-stimulating factor (GM-CSF), to generate the treatment (sipuleucel-T), which is then infused into the patient.

This presentation examined the role of GM-CSF in T cell activation and cytokine production in patients in the sipuleucel-T Phase 2 and 3 clinical trials (P07-2 ProACT and D9902B IMPACT).  For this analysis, a portion of PBMCs from each leukapheresis were cultured with GM-CSF and compared to sipuleucel-T (PBMCs cultured with PA2024) to evaluate T cell activation, cytokine production, and upregulation of the costimulatory molecules, CD54 and CD86.

The study showed a statistically significant increase in the production of a number of cytokines, including IL-2 (P<0.0001) and IFNγ (P=0.0019), from cells cultured with PA2024 compared to those cultured with GM-CSF.  Furthermore, CD54 upregulation was enhanced at week 2 in response to PA2024 but not GM-CSF.  The increased T cell activation and enhanced cytokine expression which occurred after the first infusion of sipuleucel-T also appeared to be PA2024-specific
'/>"/>

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
2. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
3. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
4. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
5. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
6. Dendreon Reports Third Quarter 2008 Financial Results
7. Dendreon Announces Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference
8. Dendreon Announces Webcast Presentation at Eleventh Annual BIO CEO & Investor Conference
9. Dendreon Reports Fourth Quarter and 2008 Year End Financial Results
10. Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer
11. Dendreon Announces Data Presentations and Webcast at AUA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/7bf7ff/cytogenetics ... new report "Cytogenetics - Technologies, Markets and ... report deals with cytogenetics in a broader sense ... the chromosome structure and identify abnormalities related to ... is also referred to as molecular cytogenetics. The ...
(Date:5/29/2015)... MILWAUKEE, WISCONSIN (PRWEB) May 29, 2015 ... oncolytic virus talimogene laherparepvec and its ability to reduce ... the treatment have been published in the Journal of ... 436 patients with stages IIIB, IIIC and IV melanoma, ... goal of the study was to evaluate the safety ...
(Date:5/29/2015)... Fort Worth, Texas (PRWEB) May 29, 2015 ... can grow. This is for a good reason--if used in ... work wonders for the offering of a business product or ... in which translation can have a positive effect on a ... product or service that anyone in the world can use, ...
(Date:5/28/2015)... , May 28, 2015 ... has announced the addition of Jain PharmaBiotech,s ... Technologies, Markets, and Companies" to their ... This report deals with therapeutic ... at improving patient care by monitoring drug ...
Breaking Biology Technology:Global Cytogenetics Market Report 2015-2024 - Technologies, Markets and Companies 2Global Cytogenetics Market Report 2015-2024 - Technologies, Markets and Companies 3Study Published in Journal of Clinical Oncology Reports Talimogene Laherparepvec Improvesdurable Responses in Patients with Advanced Melanoma 2Three Ways Translation Can Help Businesses Grow 2Global Therapeutic Drug Monitoring Market 2015-2024 2
... developed a new type of small-scale electric power generator ... and releasing of zinc oxide wires encapsulated in a ... , The new "flexible charge pump" generator is the ... by using the piezoelectric properties of zinc oxide structures ...
... group Plasma & Materials Processing (PMP) of Eindhoven University ... Leverhulme Technology Transfer Award 2008. They receive the prize ... research group) for their successful transfer of research results ... research was rewarded with the SolarWorld Junior Einstein Award. ...
... refusing to a request for a,special shareholders meeting ... directors, management of Trinity Biotech plc (Nasdaq: ... products whose,American Depository Receipts ("ADRs) are traded on ... jobs and positions in the company,outweigh the right ...
Cached Biology Technology:New small-scale generator produces alternating current by stretching zinc oxide wires 2New small-scale generator produces alternating current by stretching zinc oxide wires 3TU/e awarded for knowledge transfer to solar energy industry 2Trinity Biotech Management Refuses to Honor Call for a Special Meeting of Shareholders 2Trinity Biotech Management Refuses to Honor Call for a Special Meeting of Shareholders 3
(Date:5/11/2015)... 11, 2015 Curemark LLC, a privately held ... a new Phase III double blind, randomized, placebo-controlled clinical ... CM-AT, on all children ages 3-8 with Autism. Previously, ... III double blinded clinical trial for CM-AT in children ... the digestive enzyme chymotrypsin. This new trial will help ...
(Date:5/8/2015)... JOSE, Calif. , May 8, 2015 Synaptics ... interface solutions, today announced that members of the executive management ... J.P. Morgan 43rd Annual Technology, Media and Telecom Conference ... Waterfront Hotel in Boston, MA ... May 27, 2015 Time: 2:45pm ET Location: The New York ...
(Date:5/6/2015)... , May 6, 2015 LifeBEAM, a developer ... helmet producer, announced today that they will expand their ... world,s first bio-sensing cycling helmet and the first joint ... two new colors in order to give cyclists more ... In addition, LifeBEAM and Lazer announced their plan to ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2Synaptics to Present at Upcoming Investor Conferences 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3
... , ... ... , , , , ... ...
... The 2010 American Society for Microbiology (ASM) BD ... presented to J. Stephen Dumler, M.D., Professor, The ... Sponsored by BD Diagnostic Systems, this award recognizes ... the foundation for important applications in clinical microbiology. ...
... Following an intense study of agricultural ecosystems ... simultaneous analysis and management of a wide range ... Raudsepp-Hearne of McGill University,s Department of Geography, Elena ... Garry Peterson of the Stockholm Resilience Centre at ...
Cached Biology News:Amano USA Holdings, Inc. Announces the Acquisition of Accu-Time Systems Inc. 2Amano USA Holdings, Inc. Announces the Acquisition of Accu-Time Systems Inc. 3American Society for Microbiology honors J. Stephen Dumler 2Seeing the hidden services of nature 2
... Maximize the value of your microarray data ... support you need from consultation to extensive ... date methods. Utilize our expertise in combination ... from your own microarray experiments., ,Normalization and ...
... is a new product number, created ... If showing no availability yet, please ... (Z71,517-4) or contact customer service for ... surface, easy grip) Mfr ...
BD Falcon 850 cm Smooth-surface TufRol Roller Bottle, tissue-culture treated polystyrene, blow-molded one-piece design, with easy on/off non-vented cap, packed in double bag. (20/ca) Packaging: ...
Four siRNAs targeting your gene of interest, providing gene silencing with 100% satisfaction guaranteed High knockdown potency , High specificity for minimal off-target effects , Flexible siR...
Biology Products: